Last reviewed · How we verify
NCT06697405
Impact of Cardiopulmonary Bypass Time on Gastrointestinal Complications
trial testing Prolonged ≥ 120 minutes in Valvular Disease in 1,444 participants. Completed in 25 December 2025.
25 December 2025
Quick facts
| Lead sponsor | Hepatopancreatobiliary Surgery Institute of Gansu Province |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,444 |
| Start date | 24 December 2024 |
| Primary completion | 25 December 2025 |
| Estimated completion | 25 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Prolonged ≥ 120 minutes
Conditions studied
- Valvular Disease — all drugs for Valvular Disease →
Sponsor
Hepatopancreatobiliary Surgery Institute of Gansu Province
Who can join
Adults 18 to 75, any sex, with Valvular Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This retrospective study investigates the relationship between cardiopulmonary bypass (CPB) duration and the incidence of gastrointestinal complications (GICs) in patients undergoing heart valve replacement. Patients will be grouped into a normal CPB group (CPB \<120 minutes) and a prolonged CPB group (CPB ≥120 minutes). The study aims to determine whether prolonged CPB time is associated with a higher risk of GICs and to evaluate the outcomes and recovery process for patients who develop GICs postoperatively.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Impact of prolonged cardiopulmonary bypass on gastrointestinal complications in cardiac surgery: a retrospective cohort study.
Yang X, Lu N, Yang L, Li B, et al · · 2025 · cited 2× · PMID 40234981 · DOI 10.1186/s13741-025-00524-w
Verify or expand the search:
- PubMed search for NCT06697405
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Hepatopancreatobiliary Surgery Institute of Gansu Province trials
Trials by the same sponsor.
- NCT03104569 — Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma · NA · not yet recruiting
- NCT07321431 — The Optimal Measurement Time for the New Gallbladder Function Assessment Method · NA · recruiting
- NCT07091526 — Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer · recruiting
- NCT07039864 — A Novel Strategy for Evaluating Gallbladder Contraction Function by Ultrasound · NA · completed
- NCT06699030 — A Strategy for Gallstone Expulsion Through Dietary Therapy · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06697405 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hepatopancreatobiliary Surgery Institute of Gansu Province
- Last refreshed: 31 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06697405.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing